[1]
R. Keen, J. Pantin, N. Savage, and P. M. Dainer, “Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations”, Hematol Rep, vol. 8, no. 4, Nov. 2016.